A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Studying the long-term effects of Ibrutinib in people who were on previous trials for the drug that have now closed

Main Aims

This is a long-term study to collect data about the BTK inhibitor Ibrutinib. It also allows access to Ibrutinib to participants who were in Ibrutinib clinical trials that have now closed. Participants are given the same dose of the drug that they received previously until a point that it becomes ineffective, or the study ends.

Recruitment Criteria

• Participants can enter by invitation only.

• All participants must have participated in an ibrutinib clinical trial which has been completed.

• Patients must have received Ibrutinib for at least 6 months.

Recruitment status: Recruiting

Sponsor: Janssen Research & Development, LLC

Expected to end: 29/01/2027

Phases: Phase 2, Phase 3

Regions: East Midlands, East of England, London, North West England, Scotland, South East England, South West England, West Midlands, Yorkshire and the Humber